Sustained-release pharmaceutical composition for treatment and prevention of eye disease
Number of patents in Portfolio can not be more than 2000
United States of America Patent
Stats
-
Oct 20, 2020
Grant Date -
Aug 1, 2019
app pub date -
Feb 15, 2019
filing date -
Sep 10, 2014
priority date (Note) -
In Force
status (Latency Note)
Importance
Abstract
The present invention relates to a terpenoid derivative that has the ability to activate the Keap1/Nrf2/ARE signaling pathway and is excellent in anti-inflammatory action and cytoprotective action, and a sustained-release pharmaceutical composition effective for the treatment and prevention of a posterior eye disease caused by oxidative stress, comprising the terpenoid derivative as an active ingredient. The present invention provides a local administration-type sustained-release pharmaceutical composition for the treatment or prevention of a posterior eye disease, comprising the terpenoid derivative of the present invention as an active ingredient, wherein the sustained-release pharmaceutical composition maintains a pharmacological action thereof for 1 week or longer by the sustained release of the terpenoid derivative under physiological conditions and has a base material administrable to the vitreous body and a form administrable to the vitreous body.
First Claim
Other Claims data not available
Family
International Classification(s)
Cited Art Landscape
Patent Citation Ranking
- 0 Citation Count
- A61K Class
- 0 % this patent is cited more than
- 5 Age
Maintenance Fees
| Fee | Large entity fee | small entity fee | micro entity fee | due date |
|---|---|---|---|---|
| 7.5 Year Payment | $3600.00 | $1800.00 | $900.00 | Apr 20, 2028 |
| 11.5 Year Payment | $7400.00 | $3700.00 | $1850.00 | Apr 20, 2032 |
